The combined use of mesenchymal stromal cells and scaffolds for bone repair

Current Pharmaceutical Design

Volumn 18, Issue 13, 2012, Pages 1796-1820

  Ciapetti, Gabriela ^a   Granchi, Donatella ^a   Baldini, Nicola ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Biomaterials; Bone engineering; Bone regeneration; Cell therapy; Mesenchymal stem cells; Orthopaedics; Osteogenesis; Scaffold

Indexed keywords

BIGLYCAN; BIOCERAMICS; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; CYTOKINE; DECORIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GROWTH FACTOR; HYDROXYAPATITE; INFUSE; INTERLEUKIN 1ALPHA; LEUKEMIA INHIBITORY FACTOR; MACROGOL; METAL OXIDE; NANOMATERIAL; OP 1; POLYACRYLIC ACID; POLYCAPROLACTONE; POLYGLYCOLIDE; POLYVINYL ALCOHOL; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; SMALL INTERFERING RNA; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TISSUE SCAFFOLD; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; B LYMPHOCYTE; BONE ALLOGRAFT; BONE DEVELOPMENT; BONE MARROW BIOPSY; BONE REMODELING; BONE TISSUE; CELL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL HOMING; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; COLONY FORMING UNIT; COMPOSITE MATERIAL; CONGENITAL PSEUDARTHROSIS; DEGRADATION; DENDRITIC CELL; EMBRYONIC STEM CELL; EX VIVO STUDY; FIBROBLAST; FREEZE DRYING; GENE THERAPY; HEART INFARCTION; HUMAN; HYDROLYSIS; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MECHANOTRANSDUCTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PARACRINE SIGNALING; PLURIPOTENT STEM CELL; POROSITY; PRIORITY JOURNAL; REVIEW; RIGIDITY; SOMATIC CELL THERAPY; SPINAL CORD INJURY; STEM CELL NICHE; THROMBOCYTE RICH PLASMA; TIBIA; TISSUE ENGINEERING; TISSUE REGENERATION; TUMOR CELL; VASCULARIZATION; WETTABILITY;

ADULT; BONE AND BONES; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84860127932     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799859648     Document Type: Review

References (239)

1. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260: 920-926.
2. Baldini N, Cenni E, Ciapetti G, Granchi D, Savarino L. In: Planell JA, Best SM, Lacroix D, Merolli A, Eds. Bone repair biomaterials. Woodhead Publishing UK, 2009; pp. 69-105.
3. Gomoll AH, Farr J, Gillogly SD, Kercher J, Minas T. Surgical management of articular cartilage defects of the knee. J Bone Joint Surg Am 2010; 92: 2470-2490.
4. Hak DJ, Toker S, Yi C, Toreson J. The influence of fracture fixation biomechanics on fracture healing. Orthopedics 2010; 33: 752-755
5. Berven SH, Yaszemski MJ, Newton PO, et al. Introduction of new devices and technologies into a spine surgery practice: a review of processes and regulations. Orthopedics 2010; 33: 742-747.
6. Atesok K, Doral MN, Whipple T, et al. Arthroscopy-assisted fracture fixation. Knee Surg Sports Traumatol Arthrosc 2011; 19: 320-329.
7. Huo MH, Stockton KG, Mont MA, Parvizi J. What's new in total hip arthroplasty.J Bone Joint Surg Am 2010; 92: 2959-2972.
8. Shenaq DS, Rastegar F, Petkovic D, et al. Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials. Stem Cells Int 2010; 2010: 519028.
9. Reichert JC, Saifzadeh S, Wullschleger ME, et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials 2009; 30: 2149-2163.
10. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: An update. Injury 2005; 36S: S20-S27.
11. Tabata Y. Review- Biomaterial technology for tissue engineering applications. J R Soc Interface 2009; 6: S311-S324.
12. Hunziker E, Spector M, Libera J, et al. Translation from Research to Applications. Tissue Eng 2006, 12: 3341-3364.
13. Muschler GF, Raut VP, Patterson TE, Wenke JC, Hollinger JO. The Design and Use of Animal Models for Translational Research in Bone Tissue Engineering and Regenerative Medicine. Tissue Eng Part B: Reviews 2010; 16: 123-145.
14. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Het-erotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-247.
15. Owen M. Marrow stromal stem cells. J Cell Sci Suppl 1988; 10: 63-76.
16. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
17. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-395.
18. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
19. Habibovic P, Woodfield T, De Groot K, Van Blitterswijk C. Predictive value of in vitro and in vivo assays in bone and cartilage re-pair-what do they really tell us about the clinical performance? Adv Exp Med Biol 2006; 585: 327-360.
20. Fox JM, Chamberlain G, Ashton BA, Middleton J. Recent Advances into the understanding of mesenchymal stem cell trafficking. Brit J Haematol 2007; 137: 491-502.
21. Suzuki K, Sun R, Origuchi M, et al. Mesenchymal Stromal Cells Promote Tumor Growth Through the Enhancement of Neovascularization. Mol Med 2011 Mar 11. doi: 10.2119/molmed.2010.00157.
22. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal Stromal Cells - A Novel Treatment Modality for Tissue Repair. Ann N Y Acad Sci 2009; 1176: 101-117.
23. Leonardi E, Devescovi V, Perut F, Ciapetti G, Giunti A. Isolation, characterisation and osteogenic potential of human bone marrow stromal cells derived from the medullary cavity of the femur. Chir Organi Mov 2008; 92: 97-103.
24. Leonardi E, Ciapetti G, Baglìo SR, Devescovi V, Baldini N, Gran-chi D. Osteogenic properties of late adherent subpopulations of human bone marrow stromal cells. Histochem Cell Biol 2009; 132: 547-557.
25. Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, Da Silva CL, Cabral JMS. Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. J Cell Physiol 2010; 223: 27-35.
26. Bieback K, Schallmoser K, Kluter H, Strunk D. Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother 2008; 35: 286-294.
27. Guilak F, Estes BT, Diekman BO, Moutos FT, Gimble JM. 2010 Nicolas Andry Award: Multipotent Adult Stem Cells from Adipose Tissue for Musculoskeletal Tissue Engineering. Clin Orthop Relat Res 2010; 468: 2530-2540.
28. Skillington J, Choy L, Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol 2002; 159: 135-143.
29. Lin G, Garcia M, Ning H, et al. Defining Stem and Progenitor Cells within Adipose Tissue. Stem Cells Dev 2008; 17: 1053-1064.
30. Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O'Connor KC. Clonal Analysis of the Proliferation Potential of Human Bone Marrow Mesenchymal Stem Cells as a Function of Potency. Biotechnol. Bioeng 2011 May 2. doi: 10.1002/bit.23193
31. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. Arthritis Rheum 2006; 54: 1222-1232.
32. Friedman MS, Long MW, Hankenson KD. Osteogenic differentiation of human mesenchymal stem cells is regulated by bone morphogenetic protein-6. J Cell Biochem 2006; 98: 538-554.
33. Barlow S, Brooke G, Chatterjee K, et al. Comparison of Human Placenta- and Bone Marrow-Derived Multipotent Mesenchymal Stem Cells. Stem Cells Dev 2008; 17: 1095-1108.
34. Sessarego N, Parodi A, Podestà M, et al. Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica 2008; 9: 339-346.
35. Barachini S, Trombi L, Danti S, et al. Morpho-Functional Characterization of Human Mesenchymal Stem Cells from Umbilical Cord Blood for Potential Uses in Regenerative Medicine. Stem Cells Dev 2009; 18: 293-305.
36. Muschler GF, Nakamoto C, Griffith LG. Engineering Principles of Clinical Cell-Based Tissue Engineering. J Bone Joint Surg Am 2004; 86A: 1541-1558.
37. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. Stem Cells 2006; 24: 1294-1301.
38. Jackson WM, Nesti LJ, Tuan RS. Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells. Expert Opin Biol Ther 2010; 10: 505-517.
39. Brooke G, Cook M, Blair C, et al. Review. Therapeutic applications of mesenchymal stromal cells. Semin Cell Devel Biol 2007; 18: 846-858.
40. Lindner U, Kramer J, Rohwedel J, Schlenke P. Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology? Transfus Med Hemother 2010; 37: 75-83.
41. Jones EA, English A, Kinsey SE, et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human BM. Cytometry B Clin Cytom 2006; 70: 391-399.
42. Nombela-Arrieta C, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 2011; 12: 126-131.
43. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 2007; 131: 861-872.
44. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; 1: 39-49.
45. Vitale AM, Wolvetang E, Mackay-Sim A. Induced pluripotent stem cells: A new technology to study human diseases. Int J Bio-chem Cell Biol 2011; 43: 843-846.
46. Phinney DG, Prockop J. Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair-Current Views. Stem Cells 2007; 25: 2896-2902.
47. Granchi D, Ochoa G, Leonardi E, et al. Gene expression patterns related to osteogenic differentiation of bone marrow-derived mes-enchymal stem cells during ex vivo expansion.Tissue Eng Part C Methods 2010; 16: 511-524.
48. Kolf CM, Cho E, Tuan RS. Review. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthr Res Ther 2007; 9: 204.
49. Wlodarski KH. Properties and origin of osteoblasts. Clin Orthop Relat Res 1990; 252: 276-293.
50. Beresford JN. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Relat Res 1989; 240: 270-280.
51. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunesuppression Trends Immunol 2007; 28: 219-226.
52. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Review. Mes-enchymal stem cells: immunobiology and role in immunomodula-tion and tissue regeneration. Cytotherapy 2009; 11: 377-391.
53. Caplan AI. New Era of Cell-Based Orthopedic Therapies. Tissue Engineering: Part B 2009; 15: 195-200.
54. Cenni E, Perut F, Ciapetti G, et al. In vitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering. J Mater Sci Mater Med 2009; 20: 45-50.
55. Hak DJ, Pittman JL. Biological rationale for the intramedullary canal as a source of autograft material. Orthop Clin North Am 2010; 41: 57-61.
56. Bakker AD, Kroeze RJ, Korstjens C, de Kleine RH, Frölke JP, Klein-Nulend J. Reaming debris as a novel source of autologous bone to enhance healing of bone defects. J Biomed Mater Res A 2011; 97: 457-465.
57. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res 2005; 66: 286-294.
58. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919-926.
59. O'Driscoll SW, Saris DB, Ito Y, Fitzimmons JS. The chondrogenic potential of periosteum decreases with age. J Orthop Res 2001; 19: 95-103.
60. Gruber R, Koch H, Doll BA, Tegtmeier F, Einhorn TA, Hollinger JO. Fracture healing in the elderly patient. Exper Geront 2006; 41: 1080-1093.
61. Kuznetsov SA, Mankani MH, Bianco P, Robey PG.Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions. Stem Cell Res 2009; 2: 83-94.
62. Stenderup K, Justesen J, Eriksen EF, Rattan SI, Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. J Bone Miner Res 2001; 16: 1120-1129.
63. Kassem M, Marie PJ. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 2011; 10: 191-197.
64. Aslan H, Zilberman Y, Arbeli V, et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 2006; 12: 877-889.
65. Castano-Izquierdo H, Alvarez-Barreto J, van den Dolder J, Jansen JA, Mikos AG, Sikavitsas VI. Pre-culture period of mesenchymal stem cells in osteogenic media influences their in vivo bone forming potential. J Biomed Mater Res A 2007; 82: 129-138.
66. Ciapetti G, Ambrosio L, Marletta G, Baldini N, Giunti A. Human bone marrow stromal cells: In vitro expansion and differentiation for bone engineering. Biomaterials 2006; 27: 6150-6160.
67. Schallmoser K, Bartmann C, Rohde E, et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 2010; 95: 867-874.
68. Sun Y, Li W, Lu Z, Chen R, Ling J, Ran Q, Jilka RL, Chen XD. Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J 2011; 25: 1474-1485.
69. Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D, Koch C. How to track cellular aging of mesenchymal stromal cells? Aging 2010; 2: 224-230.
70. Liao J, Hammerick KE, Challen GA, Goodell MA, Kasper FK, Mikos AG.Investigating the role of hematopoietic stem and progenitor cells in regulating the osteogenic differentiation of mesen-chymal stem cells in vitro. J Orthop Res 2011 Apr 14. doi: 10.1002/jor.21436.
71. Thibault RA, Scott Baggett L, Mikos AG, Kasper FK. Osteogenic differentiation of mesenchymal stem cells on pregenerated extracellular matrix scaffolds in the absence of osteogenic cell culture supplements. Tissue Eng Part A 2010; 16: 431-440.
72. Hsiong SX, Carampin P, Kong HJ, Lee KY, Mooney DJ. Differentiation stage alters matrix control of stem cells. J Biomed Mater Res Part A 2008, 85: 145-156.
73. Arvidson K, Abdallah BM, Applegate LA, et al. Bone regeneration and stem cells. J Cell Mol Med 2011; 15: 718-746.
74. Rayment EA, Williams DJ. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 2010; 28: 996-1004.
75. Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010; 116: 2519-2530.
76. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362-1369.
77. Røsland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.Cancer Res 2009; 69: 5331-5339.
78. Roobrouck VD, Clavel C, Jacobs SA, et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcrip-tome and partially influenced by the culture conditions. Stem Cells 2011; 29: 871-882.
79. Granchi D, Devescovi V, Baglìo SR, et al. Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone 2010; 46: 780-788.
80. Wagoner Johnson AJ, Herschler BA. A review of the mechanical behavior of CaP and CaP/polymer composites for applications in bone replacement and repair. Acta Biomater 2011; 7: 11-30.
81. Bhushan B. Biomimetics: lessons from Nature - an overview. Phil Trans R Soc A 2009; 367: 1445-1486.
82. Coutu DL, Cuerquis J, El Ayoubi R, et al. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. Biomaterials 2011; 32: 295-305.
83. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 2005; 26: 5474-5491.
84. Clark P, Connolly P, Curtis ASG, Dow JA, Wilkinson CD. Topographical control of cell behaviour. I. Simple step cues. Development 1987; 99: 439-448.
85. Bettinger CJ, Langer R, Borenstein JT. Engineering Substrate Micro- and Nanotopography to Control Cell Function. Angew Chem Int Ed Engl 2009; 48: 5406-5415.
86. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Molec Cell Biol 2006; 7: 211-224.
87. Vagaska B, Bacakova L, Filova E, Balik K. Osteogenic Cells on Bio-Inspired Materials for Bone Tissue Engineering. Physiol Res 2010; 59: 309-322.
88. Perez-Castillejos R. Replication of the 3D architecture of tissues. Materials Today 2010; 13: 32-41.
89. Shanmugasundaram S, Chaudhry H, Arinzeh TL. Microscale versus nanoscale scaffold architecture for mesenchymal stem cell chondrogenesis. Tissue Eng Part A 2011; 17: 831-840.
90. Bouwmeester H, Lynch I, Marvin HJ, et al. Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology 2011; 5: 1-11.
91. Webster TJ, Siegel RW, Bizios R. Design and evaluation of nano-phase alumina for orthopaedic/dental applications. Nanostruct Mater 1999; SI: 983-986.
92. Stanford CM. Surface Modification of Biomedical and Dental Implants and the Processes of Inflammation, Wound Healing and Bone Formation. Int J Mol Sci 2010; 11: 354-369.
93. Marletta G, Ciapetti G, Satriano C, et al. Improved osteogenic differentiation of human marrow stromal cells cultured on ion-induced chemically structured poly-epsilon-caprolactone. Biomate-rials 2007; 28: 1132-1140.
94. Watari F, Takashi N, Yokoyama A, et al. Material nanosizing effect on living organisms: non-specific, biointeractive, physical size effects. J R Soc Interface 2009; 6 Suppl 3: S371-S388.
95. Dalby MJ, Gadegaard N, Tare R, et al. The control of human mes-enchymal cell differentiation using nanoscale symmetry and disorder. Nat Mater 2007; 6: 997-1003.
96. McNamara LE, McMurray RJ, Biggs MJP, Kantawong F, Oreffo ROC, Dalby MJ. Nanotopographical Control of Stem Cell Differentiation. J Tissue Engineering 2010, Article ID 120623, 13 pages.
97. Bakacova L, Filova E, Kubies D, et al. Adhesion and growth of vascular smooth muscle cells in cultures on bioactive RGD pep-tide-carrying polylactides. J Mater Sci Mater Med 2007: 18: 1317-1323.
98. Arima Y, Iwata H. Effect of wettability and surface functional groups on protein adsorption and cell adhesion using well-defined mixed self-assembled monolayers. Biomaterials 2007; 28: 3074-3082.
99. Zhao G, Zinger O, Schwartz Z, Wieland M, Landolt D, Boyan BD. Osteoblast-like cells are sensitive to submicron-scale surface structure. Clin Oral Implants Res 2006; 17: 258-264.
100. Rupp F, Scheideler L, Olshanska N, De Wild M, Wieland M, Geis-Gerstorfer J. Enhancing surface free energy and hydrophilicity through chemical modification of microstructured titanium implant surfaces. J Biomed Mater Res 2006; 76A: 323-334.
101. Olivares-Navarrete R, Hyzy SL, Hutton DL, et al. Direct and indirect effects of microstructured titanium substrates on the induction of mesenchymal stem cell differentiation towards the osteoblast lineage. Biomaterials 2010; 31: 2728-2735.
102. Junker R, Dimakis A, Thoneick M, Jansen JA. Effects of implant surface coatings and composition on bone integration: a systematic review. Clin Oral Impl Res 2009,20 (Suppl. 4): 185-206.
103. Kim EJ, Boehm CA, Mata A, Fleischman AJ, Muschler GF, Roy S. Post microtextures accelerate cell proliferation and osteogenesis. Acta Biomater 2010; 6: 160-169.
104. Olivares-Navarrete R, Hyzy SL, Hutton DL, et al. Role of non-canonical Wnt signaling in osteoblast maturation on microstruc-tured titanium surfaces. Acta Biomater 2011; 7: 2740-2750.
105. Engler AJ, Sen S, Lee Sweeney H, Discher DE. Matrix Elasticity Directs Stem Cell Lineage Specification. Cell 2006; 126: 677-689.
106. Bueno EM, Glowacki J. Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol 2009; 5: 685-697.
107. Guarino V, Taddei P, Di Foggia M, Fagnano C, Ciapetti G, Am-brosio L. The influence of hydroxyapatite particles on in vitro degradation behavior of poly epsilon-caprolactone-based composite scaffolds. Tissue Eng Part A 2009; 15: 3655-3668.
108. Khan Y, Yaszemski MJ, Mikos AG, Laurencin CT. Tissue Engineering of Bone: Material and Matrix Considerations. J Bone Joint Surg Am 2008; 90 (Suppl. 1): 36-42.
109. Low KL, Tan SH, Zein SHS, Roether JA, Mouriño V, Boccaccini AR. Calcium phosphate-based composites as injectable bone substitute materials. J Biomed Mater Res Part B: Applied Biomaterials 2010; 94: 273-286.
110. Perut F, Montufar EB, Ciapetti G, et al. Novel soybean/gelatine-based bioactive and injectable hydroxyapatite foam: material properties and cell response. Acta Biomater 2011; 7: 1780-1787.
111. Tan Q, Li S, Ren J, Chen C. Fabrication of porous scaffolds with a controllable microstructure and mechanical properties by porogen fusion technique. Int J Mol Sci 2011; 12: 890-904.
112. Hutmacher DW, Cool S. Concepts of scaffold-based tissue engineering- the rationale to use solid free-form fabrication techniques. Cell Mol Med 2007; 11: 654-669.
113. Moroni L, de Wijn JR, van Blitterswijk CA. Integrating novel technologies to fabricate smart scaffolds. J Biomater Sci Polym Ed 2008; 19: 543-572.
114. Roshan-Ghias A, Pioletti DP. Surgical preparation of bone-scaffold interface is critical for bone regeneration inside tissue engineering scaffold. J Orthop Res 2011; 29: 767-772.
115. Lacroix D, Planell JA, Prendergast PJ. Computer-aided design and finite element modelling of biomaterial scaffolds for bone tissue engineering. Philos Transact A Math Phys Eng Sci 2009; 367: 1993-2009.
116. Boccaccio A, Ballini A, Pappalettere C, Tullo D, Cantore S, De-siate A. Finite element method (FEM), mechanobiology and biomimetic scaffolds in bone tissue engineering. Int J Biol Sci 2011; 7: 112-132.
117. Byrne DP, Lacroix D, Planell JA, Kelly DJ, Prendergast PJ. Simulation of tissue differentiation in a scaffold as a function of porosity, Young's modulus and dissolution rate: application of mechano-biological models in tissue engineering. Biomaterials 2007; 28: 5544-5554.
118. von der Mark K, Park J, Bauer S, Schmuki P. Nanoscale engineering of biomimetic surfaces: cues from the extracellular matrix. Cell Tissue Res 2010; 339: 131-153.
119. Breen A, O'Brien T, Pandit A. Fibrin as a delivery system for therapeutic drugs and biomolecules.Tissue Eng Part B Rev 2009; 15: 201-214.
120. Dorozhkin SV. Nanosized and nanocrystalline calcium orthophos-phates. Acta Biomater 2010; 6: 715-734.
121. Agrawal CM, Ray RB. Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. J Biomed Mater Res 2001; 55: 141-150.
122. Corsi KA, Schwarz EM, Mooney DJ, Huard J. Regenerative Medicine in Orthopaedic Surgery. J Orthop Res 2007; 25: 1261-1268.
123. Lichte P, Pape HC, Pufe T, Kobbe P, Fischer H. Scaffolds for bone healing: Concepts, materials and evidence. Injury 2011; 42: 569-573.
124. Gloria A, De Santis R, Ambrosio L. Polymer-based composite scaffolds for tissue engineering. J Appl Biomater Biomech 2010; 8: 57-67.
125. Baroli B. From Natural Bone Grafts to Tissue Engineering Therapeutics: Brainstorming on Pharmaceutical Formulative Requirements and Challenges. J Pharm Sci 2009; 98: 1317-1375.
126. McManus AJ, Doremus RH, Siegel RW, Bizios R. Evaluation of cytocompatibility and bending modulus of nanoceramic/polymer composites. J Biomed Mater Res A 2005; 72: 98-106.
127. Uriel S, Labay E, Francis-Sedlak M, et al. Extraction and Assembly of Tissue-Derived Gels for Cell Culture and Tissue Engineering. Tissue Eng Part C 2009; 15: 309-320.
128. Andriola Silva AK, Richard C, Bessodes M, Scherman D, Merten OW. Growth Factor Delivery Approaches in Hydrogels. Biomac-romolecules 2009; 10: 9-18.
129. Pepe A, Bochicchio B, Tamburro AM. Supramolecular organization of elastin and elastin-related nanostructured biopolymers. Nanomedicine (Lond) 2007; 2: 203-218.
130. Sengupta D, Heilshorn SC. Protein-Engineered Biomaterials: Highly Tunable Tissue Engineering Scaffolds. Tissue Eng Part B 2010; 16: 285-293.
131. Wang XJ, Huang H, Yang F, et al. Ectopic study of tissue-engineered bone complex with enamel matrix proteins, bone marrow stromal cells in porous calcium phosphate cement scaffolds, in nude mice. Cell Prolif 2011; 44: 274-282.
132. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13: 81-88.
133. Neuss S, Apel C, Buttler P, Denecke B, et al. Assessment of stem cell/biomaterial combinations for stem cell-based tissue engineering. Biomaterials 2008; 29: 302-313.
134. Pountos I, Georgouli T, Kontakis G, Giannoudis PV. Efficacy of minimally invasive techniques for enhancement of fracture healing: evidence today. Int Orthop 2010; 34: 3-12.
135. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005; 87: 1430-1437.
136. Fiorentini E, Granchi D, Leonardi E, Baldini N, Ciapetti G. Effects of osteogenic differentiation inducers on in vitro expanded adult mesenchymal stromal cells. Int J Artif Organs 2011; 34(10): 998-1011.
137. Horn P, Bork S, Wagner W. Standardized isolation of human mes-enchymal stromal cells with red blood cell lysis. Methods Mol Biol 2011; 698: 23-35.
138. Mauney JR, Kirker-Head C, Abrahamson L, Gronowicz G, Volloch V, Kaplan DL. Matrix-mediated retention of in vitro osteogenic differentiation potential and in vivo bone-forming capacity by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion. J Biomed Mater Res A 2006; 79: 464-475.
139. Chen XD. Extracellular Matrix Provides an Optimal Niche for the Maintenance and Propagation of Mesenchymal Stem Cells. Birth Defects Res (Part C) 2010; 90: 45-54.
140. Lai Y, Sun Y, Skinner CM, et al. Reconstitution of marrow-derived extracellular matrix ex vivo: a robust culture system for expanding large-scale highly functional human mesenchymal stem cells. Stem Cells Dev 2010; 19: 1095-1107.
141. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Bi-ochem Biophys Res Commun 2007; 358: 948-953.
142. Felka T, Schäfer R, De Zwart P, Aicher WK. Animal serum-free expansion and differentiation of human mesenchymal stromal cells. Cytotherapy 2010; 12: 143-153.
143. Cordonnier T, Langonné A, Sohier J, et al. Consistent osteoblastic differentiation of human mesenchymal stem cells with bone morphogenetic protein 4 and low serum. Tissue Eng Part C Methods 2011; 17: 249-259.
144. Oskowitz A, McFerrin H, Gutschow M, Carter ML, Pochampally R. Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic. Stem Cell Res 2011; 6: 215-225.
145. Gentleman E, Swain RJ, Evans ND, et al. Comparative materials differences revealed in engineered bone as a function of cell-specific differentiation. Nat Mater 2009; 8: 763-770.
146. Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O'Connor KC. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010; 28: 788-798.
147. Ma J, van den Beucken JJJP, Yang F, et al. Coculture of Os-teoblasts and Endothelial Cells: Optimization of Culture Medium and Cell Ratio. Tissue Eng Part C 2011; 17: 349-357.
148. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 9-20.
149. Davies JE. Understanding peri-implant endosseous healing. J Dent Educ 2003; 67: 932-949.
150. Dellatore SM, Garcia AS, Miller WM. Mimicking stem cell niches to increase stem cell expansion. Curr Opin Biotechnol 2008; 19: 534-540.
151. Engel E, Michiardi A, Navarro M, Lacroix D, Planell JA. Review. Nanotechnology in regenerative medicine: the materials side. Trends in Biotechnology 2008; 26: 39-47.
152. Buxboim A, Rajagopal K, Brown AE, Discher DE. How deeply cells feel: methods for thin gels. J Phys: Condens Matter 2010; 22: 194116 (10pp).
153. Uebersax L, Merkle HP, Meinel L. Biopolymer-Based Growth Factor Delivery for Tissue Repair: From Natural Concepts to Engineered Systems. Tissue Eng Part B 2009; 15: 263-289.
154. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008; 2: 81-96.
155. Axelrad TW, Steen B, Lowenberg DW, Creevy WR, Einhorn TA. Heterotopic ossification after the use of commercially available re-combinant human bone morphogenetic proteins in four patients. J Bone Joint Surg Br 2008; 90: 1617-1622.
156. Gugala Z, Davis AR, Fouletier-Dilling CM, Gannon FH, Lindsey RW, Olmsted-Davis EA. Adenovirus BMP2-induced osteogenesis in combination with collagen carriers. Biomaterials 2007; 28: 4469-4479.
157. Bais MV, Wigner N, Young M, et al. BMP2 is essential for post natal osteogenesis but not for recruitment of osteogenic stem cells. Bone 2009; 45: 254-266.
158. Nauth A, Giannoudis PV, Einhorn TA, et al. Growth Factors: Beyond Bone Morphogenetic Proteins. J Orthop Trauma 2010; 24: 543-546.
159. Williams DF. On the nature of biomaterials. Biomaterials 2009; 30: 5897-5909.
160. Garrison KR, Shemilt I, Donell S, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; 6: CD006950.
161. Lau TT, Wang DA. Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther 2011; 11: 189-197.
162. Trombi L, Mattii L, Pacini S, et al. Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. J Orthop Res 2008; 26: 176-183.
163. Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR. Buffered Platelet-Rich Plasma Enhances Mesenchymal Stem Cell Proliferation and Chondrogenic Differentiation. Tissue Eng Part C 2009; 15: 1-5.
164. Chevallier N, Anagnostou F, Zilber S, et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Bio-materials 2010; 31: 270-278.
165. Dallari D, Savarino L, Stagni C, et al. Enhanced tibial osteotomy healing with use of bone grafts supplemented with platelet gel or platelet gel and bone marrow stromal cells. J Bone Joint Surg Am 2007; 89: 2413-2420.
166. Kon E, Filardo G, Delcogliano M, et al. Platelet autologous growth factors decrease the osteochondral regeneration capability of a col-lagen-hydroxyapatite scaffold in a sheep model. BMC Musculoske-let Disord 2010; 11: 220.
167. M. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing. Acta Orthop Suppl 2007; 78: 1-64.
168. Aslan H, Zilberman Y, Arbeli V, Sheyn D, Matan Y, Liebergall M, Li JZ, Helm GA, Gazit D, Gazit Z. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 2006; 12: 877-889.
169. Jo J, Tabata Y. Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J Pharm Biopharm 2008; 68: 90-104.
170. Christ GJ, Chen AF. The grand challenge for integrative and regenerative pharmacology. Front Pharmacol 2011; 2: 1-1.
171. Eifler AC, Thaxton CS.Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol 2011; 726: 325-338.
172. Andersen MØ, Nygaard JV, Burns JS, Raarup MK, Nyengaard JR, Bünger C, Besenbacher F, Howard KA, Kassem M, Kjems J. SIRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells. Mol Ther 2010; 18: 2018-2027.
173. Rujitanaroj PO, Wang YC, Wang J, Chew SY. Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications. Biomaterials 2011; 32: 5915-5923.
174. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084.
175. Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 2008; 15: 100-114.
176. Davis GE, Bayless KJ, Mavila, A. Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat Rec 2002; 268: 252-275.
177. Unger RE, Sartoris A, Peters K, et al. Tissue-like self-assembly in cocultures of endothelial cells and osteoblasts and the formation of microcapillary-like structures on three-dimensional porous bioma-terials. Biomaterials 2007; 28: 3965-3976.
178. Burns JS, Kristiansen M, Kristensen LP, Larsen KH, Nielsen MO, Christiansen H, Nehlin J, Andersen JS, Kassem M. Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. PLoS One 2011; 6(7): e21888.
179. Watt SM, Athanassopoulos A, Harris AL, Tsaknakis G. Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. J R Soc Interface 2010; 7 (Suppl 6): S731-S751.
180. Muller D, Chim H, Bader A, Whiteman M, Schantz JT. Vascular guidance: microstructural scaffold patterning for inductive neovas-cularization. Stem Cells Int 2010; 2011: 547247.
181. Kirkpatrick CJ, Fuchs S, Unger RE. Co-culture systems for vascu-larization - Learning from nature. Adv Drug Deliv Rev 2011 Jan 31.
182. Xue Y, Xing Z, Hellem S, Arvidson K, Mustafa K. Endothelial cells influence the osteogenic potential of bone marrow stromal cells. Biomed Eng Online 2009; 8: 34.
183. Cenni E, Ciapetti G, Granchi D, et al. Endothelial cells incubated with platelet-rich plasma express PDGF-B and ICAM-1 and induce bone marrow stromal cell migration. J Orthop Res 2009; 27: 1493-1498.
184. Saleh FA, Whyte M, Ashton P, Genever PG. Regulation of Mesen-chymal Stem Cell Activity by Endothelial Cells. Stem Cells Dev 2010; 20(3): 391-403.
185. Kaully T, Kaufman-Francis K, Lesman A, Levenberg S. Vasculari-zation-The Conduit to Viable Engineered Tissues. Tissue Engineering: Part B 2009; 15: 159-169.
186. Coelho PG, Cardaropoli G, Suzuki M, Lemons JE. Early healing of nanothickness bioceramic coatings on dental implants. An experimental study in dogs. J Biomed Mat Res Part B: Appl Biomaterials 2009; 88: 387-393.
187. Einhorn TA, Lane JM, Burstein AH, Kopman CR, Vigorita VJ. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. Bone Joint Surg Am 1984; 66: 274-279.
188. Gugala Z, Lindsey RW, Gogolewski S. New approaches in the treatment of critical-size segmental defects in long bones. Macro-mol Symp 2007; 253: 147-161.
189. Horner EA, Kirkham J, Wood D, et al. Long Bone Defect Models for Tissue Engineering Applications: Criteria for Choice. Tissue Eng Part B 2010; 16: 263-271.
190. Garcia P, Herwerth S, Matthys R, et al. The Locking Mouse Nail-A new implant for standardized stable osteosynthesis in mice. J Surg Res 2011; 169: 220-226
191. Reichert JC, Epari DR, Wullschleger ME, et al. Establishment of a Preclinical Ovine Model for Tibial Segmental Bone Defect Repair by Applying Bone Tissue Engineering Strategies. Tissue Eng 2010; 16: 93-104.
192. Argintar E, Edwards S, Delahay J. Bone morphogenetic proteins in orthopaedic trauma surgery. Injury 2010 Dec 7.; 42: 730-734.
193. Dimitriou R, Jones E, Mc Gonagle D, Giannoudis PV. Bone regeneration: Current concepts and future directions. BMC Med 2011; 9: 66.
194. Tamama K, Kawasaki H, Wells A. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol 2010; 2010: 795385.
195. Shen B, Wei A, Whittaker S, et al. The role of BMP-7 in chondro-genic and osteogenic differentiation of human bone marrow mul-tipotent mesenchymal stromal cells in vitro. J Cell Biochem 2010; 109: 406-416.
196. Salvadè A, Della Mina P, Gaddi D, et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C 2010; 16: 201-214.
197. Arcos D, Izquierdo-Barba I, Vallet-Regí M. Promising trends of bioceramics in the biomaterials field. J Mater Sci Mater Med 2009; 20: 447-455.
198. LeGeros RZ. Properties of osteoconductive biomaterials: Calcium phosphates. Clin Orthop Relat Res 2002; 81-98.
199. Hing K. Bioceramic bone graft substitutes: influence of porosity and chemistry. Int J Appl Ceram Technol 2005; 2: 184-199.
200. Zhang MY, Ye C, Erasquin UJ, Huynh T, Cai C, Cheng GJ. Laser engineered multilayer coating of biphasic calcium phosphate/titanium nanocomposite on metal substrates. ACS Appl Mater Interfaces 2011; 3: 339-350.
201. Park SH, Tofighi A, Wang X, et al. Calcium phosphate combination biomaterials as human mesenchymal stem cell delivery vehicles for bone repair. J Biomed Mater Res Part B: Appl Biomater 97B 2011; 97: 235-244.
202. Kon E, Muraglia A, Corsi A, et al. Autologous bone marrow stro-mal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res 2000; 49: 328-337.
203. Arinzeh TL, Tran T, McAlary J, Daculsi G. A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation. Biomaterials 2005; 26: 368.
204. Mankani MH, Kuznetsov SA, Wolfe RM, Marshall GW, Robey PG. In vivo bone formation by human bone marrow stromal cells: reconstruction of the mouse calvarium and mandible. Stem Cells 2006; 24: 2140-2149.
205. Mankani MH, Kuznetsov SA, Shannon B, et al. Canine cranial reconstruction using autologous bone marrow stromal cells. Am J Pathol 2006; 168: 542-550.
206. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells.N Engl J Med 2001; 344: 385-386.
207. Piersanti S, Sacchetti B, Funari A, et al. Lentiviral transduction of human postnatal skeletal (stromal, mesenchymal) stem cells: in vivo transplantation and gene silencing. Calcif Tissue Int 2006; 78: 372-384.
208. Bansal S, Chauhan V, Sharma S, Maheshwar R, Juyal A, Raghu-vanshi S. Evaluation of hydroxyapatite and beta-tricalcium phosphate mixed with bone marrow aspirate as a bone graft substitute for posterolateral spinal fusion. Indian J Orthopaed 2009; 43: 234-239.
209. Chatterjea A, Meijer G, van Blitterswijk C, de Boer J. Clinical application of human mesenchymal stromal cells for bone tissue engineering. Stem Cells Int 2010; 2010: 215625.
210. Liu H, Yazici H, Ergun C, Webster TJ, Bermek H. An in vitro evaluation of the Ca/P ratio for the cytocompatibility of nano-to-micron particulate calcium phosphates for bone regeneration. Acta Biomater 2008; 4: 1472-1479.
211. Jäger M, Herten M, Fochtmann U, et al. Bridging the gap: bone marrow aspiration concentrate reduces autologous bone grafting in osseous defects. J Orthop Res 201; 29: 173-180.
212. Lan Levengood SK, Polak SJ, Wheeler MB, et al. Multiscale os-teointegration as a new paradigm for the design of calcium phosphate scaffolds for bone regeneration. Biomaterials 2010; 31: 3552-3563.
213. Tran N, Webster TJ. Nanotechnology for bone materials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1: 336-351.
214. Du C, Cui FZ, Zhu XD, de Groot K. Three dimensional nano-HAP/collagen matrix loading with osteogenic cells in organ culture. J Biomed Mater Res 1999; 44: 407-415.
215. Sang L, Huang J, Luo D, Chen Z, Li X. Bone-like nanocomposites based on self-assembled protein-based matrices with Ca2+ capturing capability. J Mater Sci Mater Med 2010; 21: 2561-2568.
216. Ciapetti G, Ambrosio L, Savarino L, et al. Osteoblast growth and function in porous poly e-caprolactone matrices for bone repair: a preliminary study. Biomaterials 2003; 24: 3815-3824.
217. Guarino V, Causa F, Netti PA, et al. The role of hydroxyapatite as solid signal on performance of PCL porous scaffolds for bone tissue regeneration. J Biomed Mater Res B Appl Biomater 2008; 86B: 548-557.
218. Yu H, VandeVord PJ, Mao L, Matthew HW, Wooley PH, Yang SY. Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials 2009; 30: 508-517.
219. Marletta G, Ciapetti G, Satriano C, Pagani S, Baldini N. The effect of irradiation modification and RGD sequence adsorption on the response of human osteoblasts to polycaprolactone. Biomaterials 2005; 26: 4793-4804.
220. Amato I, Ciapetti G, Pagani S, Marletta G, Satriano C, Baldini N, Granchi D. Expression of cell adhesion receptors in human os-teoblasts cultured on biofunctionalized poly-(epsilon-caprolactone) surfaces. Biomaterials 2007; 28: 3668-3678.
221. Massia SP, Hubbell JA. An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation. J Cell Biol 1991; 114: 1089-1100.
222. Régent M, Planus E, Bouin AP et al. Specificities of beta1 integrin signaling in the control of cell adhesion and adhesive strength. Eur J Cell Biol 2011; 90: 261-269.
223. Bell BF, Schuler M, Tosatti S, Textor M, Schwartz Z, Boyan BD. Osteoblast response to titanium surfaces functionalized with extracellular matrix peptide biomimetics. Clin Oral Implants Res 22, 865-872.
224. Santiago LY, Nowak RW, Rubin JP, Marra KG. Peptide-surface modification of poly(caprolactone) with laminin-derived sequences for adipose-derived stem cell applications. Biomaterials 2006; 27: 2962-2969.
225. Salasznyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE. Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. J Biomed Bio-technol 2004; 2004: 24-34.
226. Hidalgo-Bastida LA, Cartmell SH. Mesenchymal stem cells, os-teoblasts and extracellular matrix proteins: enhancing cell adhesion and differentiation for bone tissue engineering. Tissue Eng Part B Rev 2010; 16: 405-412.
227. Phipps MC, Clem WC, Catledge SA, et al. Mesenchymal stem cell responses to bone-mimetic electrospun matrices composed of poly-caprolactone, collagen I and nanoparticulate hydroxyapatite. PLoS One 2011; 6(2): e16813.
228. Jeon O, Rhie JW, Kwon IK, Kim JH, Kim BS, Lee SH. In vivo bone formation following transplantation of human adipose-derived stromal cells that are not differentiated osteogenically. Tissue Eng Part A 2008; 14: 1285-1294.
229. Kang JM, Kang SW, La WG, Yang YS, Kim BS. Enhancement of in vivo bone regeneration efficacy of osteogenically undifferenti-ated human cord blood mesenchymal stem cells. J Biomed Mater Res A 2010; 93: 666-672.
230. Lyons FG, Al-Munajjed AA, Kieran SM, et al. The healing of bony defects by cell-free collagen-based scaffolds compared to stem cell-seeded tissue engineered constructs. Biomaterials 2010; 31: 9232-9243.
231. Uccelli A, Moretta L, Pistoia V. Mesenchymal sem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
232. Panetta NJ, Gupta DM, Quarto N, Longaker MT. Mesenchymal stem cells for tissue engineering. Panminerva Med 2009; 51: 25-41.
233. Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem 2010; 111: 249-257.
234. Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010; 116: 2519-2530.
235. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev 2011; 10: 93-103.
236. Jones E, Yang X.Mesenchymal stem cells and bone regeneration: Current status. Injury 2011; 42: 562-568.
237. Gòmez-Barrena E, Rosset P, Muller I, et al. Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med 2011; 15: 1266-1286.
238. Rebulla P, Lecchi L, Lazzari L, et al. Special report. Development of a biological resource center for cellular therapy and biobanking in a public polyclinic university hospital. Biologicals 2008; 36: 79-87.
239. McMurray RJ, Gadegaard N, Tsimbouri PM, Burgess KV, McNa-mara LE, Tare R, Murawski K, Kingham E, Oreffo RO, Dalby MJ Nanoscale surfaces for the long-term maintenance of mesenchymal stem cell phenotype and multipotency. Nat Mater 2011; 10: 637-644.